Even though regulatory bodies like the EMA and FDA cannot work in tandem with industry and academia, they do share a common goal: to develop and launch new drugs that improve society's wellbeing.

TI Pharma brings all stakeholders to the same table. It acts as a neutral platform where common ground can be created and conflicting interests can be mediated, jointly working towards an improved and innovation-friendly regulatory framework.

TI Pharma enables several such partnerships, including:

  • Escher: An international, multi-stakeholder platform for regulatory sciences activities to optimize guidance, policy and regulations in the development of medicines and medical technology
  • Non-Biological Complex Drugs Working Group: Working group investigating science-based approval and post-approval standards for non-biological complex drugs

“TI Pharma has developed frameworks in which academia and industry bring their ideas together and they work on the best ideas together.”

Share this page: